CY2017048I2 - Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης - Google Patents

Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης

Info

Publication number
CY2017048I2
CY2017048I2 CY2017048C CY2017048C CY2017048I2 CY 2017048 I2 CY2017048 I2 CY 2017048I2 CY 2017048 C CY2017048 C CY 2017048C CY 2017048 C CY2017048 C CY 2017048C CY 2017048 I2 CY2017048 I2 CY 2017048I2
Authority
CY
Cyprus
Prior art keywords
stavrosporine
derivatives
new pharmaceutical
pharmaceutical uses
new
Prior art date
Application number
CY2017048C
Other languages
English (en)
Other versions
CY2017048I1 (el
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017048(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2017048I2 publication Critical patent/CY2017048I2/el
Publication of CY2017048I1 publication Critical patent/CY2017048I1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY2017048C 2003-06-18 2017-12-22 Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης CY2017048I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
PCT/EP2004/006562 WO2004112794A2 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives
EP04740016A EP1638574B1 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives

Publications (2)

Publication Number Publication Date
CY2017048I2 true CY2017048I2 (el) 2018-09-05
CY2017048I1 CY2017048I1 (el) 2018-09-05

Family

ID=33539193

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100627T CY1110179T1 (el) 2003-06-18 2010-07-06 Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
CY2017048C CY2017048I1 (el) 2003-06-18 2017-12-22 Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20101100627T CY1110179T1 (el) 2003-06-18 2010-07-06 Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης

Country Status (24)

Country Link
US (2) US8575146B2 (el)
EP (1) EP1638574B1 (el)
JP (2) JP5057780B2 (el)
CN (2) CN100457111C (el)
AT (1) ATE464052T1 (el)
AU (1) AU2004248909B2 (el)
BE (1) BE2017C067I2 (el)
BR (1) BRPI0411563B8 (el)
CA (2) CA2527703C (el)
CY (2) CY1110179T1 (el)
DE (1) DE602004026578D1 (el)
DK (1) DK1638574T3 (el)
ES (1) ES2344700T3 (el)
FR (1) FR17C1063I2 (el)
HK (1) HK1095519A1 (el)
HU (1) HUS000503I2 (el)
LU (1) LUC00055I9 (el)
MX (1) MXPA05013722A (el)
NL (1) NL300917I2 (el)
PL (1) PL1638574T3 (el)
PT (1) PT1638574E (el)
SI (1) SI1638574T1 (el)
TW (1) TWI324604B (el)
WO (1) WO2004112794A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
KR101153647B1 (ko) 2003-11-18 2012-06-18 노파르티스 아게 Ｋｉｔ 돌연변이형에 대한 저해제
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
CN101022799A (zh) * 2004-07-19 2007-08-22 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
RU2445960C2 (ru) * 2005-05-02 2012-03-27 Новартис Аг Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
AU2006271652B2 (en) * 2005-07-20 2010-04-29 Peter Valent Compositions for treatment of systemic mastocytosis
CA2629478C (en) 2005-11-14 2013-10-15 Universitat Zurich Staurosporine derivatives for use in alveolar rhabdomyosarcoma
WO2009092442A1 (en) * 2008-01-23 2009-07-30 Universidad De Barcelona Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
WO2012064981A2 (en) 2010-11-10 2012-05-18 National Jewish Health Methods to test allergic conditions
US20210403495A1 (en) 2018-11-01 2021-12-30 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020097261A1 (en) * 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) * 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
ES2134789T3 (es) 1991-05-09 1999-10-16 Neurim Pharma 1991 Composiciones que contienen melatonina.
AR004480A1 (es) 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
EP0912184B1 (en) * 1996-06-25 2002-09-25 Cephalon, Inc. Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6093740A (en) 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AU4423799A (en) * 1998-06-04 1999-12-20 Cornell Research Foundation Inc. Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
MXPA03005139A (es) 2000-12-08 2004-01-29 Ortho Mcneil Pharm Inc Compuestos macroheterociclicos utiles como inhibidores de cinasa.
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
JP2004536097A (ja) * 2001-06-29 2004-12-02 アブ サイエンス 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法
CA2462657C (en) * 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
JPWO2004091663A1 (ja) 2003-04-18 2006-07-06 協和醗酵工業株式会社 神経再生薬
EP1637161A4 (en) 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
KR101153647B1 (ko) 2003-11-18 2012-06-18 노파르티스 아게 Ｋｉｔ 돌연변이형에 대한 저해제

Also Published As

Publication number Publication date
US20130289018A1 (en) 2013-10-31
ES2344700T3 (es) 2010-09-03
DK1638574T3 (da) 2010-08-02
CY1110179T1 (el) 2015-01-14
DE602004026578D1 (de) 2010-05-27
NL300917I2 (nl) 2018-01-09
EP1638574A2 (en) 2006-03-29
PT1638574E (pt) 2010-07-14
HUS000503I2 (hu) 2021-03-29
EP1638574B1 (en) 2010-04-14
JP2012144572A (ja) 2012-08-02
BRPI0411563B8 (pt) 2021-05-25
CN100457111C (zh) 2009-02-04
BE2017C067I2 (el) 2023-08-09
CA2527703C (en) 2012-10-23
CA2527703A1 (en) 2004-12-29
LUC00055I1 (el) 2017-12-14
CY2017048I1 (el) 2018-09-05
BRPI0411563B1 (pt) 2019-09-24
HUS1700053I1 (hu) 2018-01-29
CN1805749A (zh) 2006-07-19
PL1638574T3 (pl) 2010-09-30
US8575146B2 (en) 2013-11-05
MXPA05013722A (es) 2006-03-08
BRPI0411563A (pt) 2006-08-01
SI1638574T1 (sl) 2010-08-31
LUC00055I2 (el) 2018-02-21
US20070299049A1 (en) 2007-12-27
HK1095519A1 (en) 2007-05-11
AU2004248909B2 (en) 2008-05-08
ATE464052T1 (de) 2010-04-15
FR17C1063I1 (el) 2018-02-16
TW200512213A (en) 2005-04-01
WO2004112794A3 (en) 2005-06-16
CA2785950A1 (en) 2004-12-29
WO2004112794A2 (en) 2004-12-29
FR17C1063I2 (fr) 2019-05-03
LUC00055I9 (el) 2022-11-09
JP2006527727A (ja) 2006-12-07
CN101164539A (zh) 2008-04-23
JP5057780B2 (ja) 2012-10-24
AU2004248909A1 (en) 2004-12-29
NL300917I1 (nl) 2017-12-12
TWI324604B (en) 2010-05-11

Similar Documents

Publication Publication Date Title
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
CY2018005I1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
IS2656B (is) Nýjar besímídasólafleiður
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
NO20054136D0 (no) Imidazol-4-yl-etynyl-pyridin-derivater
ATE420066T1 (de) Amidoacetonitrilderivate
NO20054224D0 (no) Nye 2-pyridinkarboksamidderivater
ATE499347T1 (de) Amidderivate
ATE352550T1 (de) Chinazolinderivate
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
DK1587478T3 (da) Farmaceutisk sammensætning
DK1622612T3 (da) Farmaceutisk formulering af natriumsaltet af telmitarsan
DK1652843T3 (da) Amidderivater
IS8045A (is) Púrín-6-ón-afleiður
NO20043937L (no) Anvendelse av vitamin D sammensetninger
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
ATE449064T1 (de) Amidoacetonitrilderivate
NO20034952D0 (no) Farmasöytiske forbindelser
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
NO20044164L (no) Farmasoytiske sammensetninger
DE112004001429D2 (de) Pharmazeutischer Wirkstoff
PT1467737E (pt) Composicao farmaceutica orodispersivel de piribedil
ITRM20030053A1 (it) Associazione di farmaci antidiabetici.
FI20030224A0 (fi) Uudet farmaseuttiset käytöt
DOP2003000794A (es) Nuevos compuestos farmaceuticos